Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Docetaxel Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 4/20 | 0.99 |
| ▸ | TUBB known ✓ | P07437 | 4/20 | 0.99 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 4/20 | 0.99 |
| ▸ | TUBA1B known ✓ | P68363 | 4/20 | 0.99 |
| ▸ | TUBA4A known ✓ | P68366 | 4/20 | 0.99 |
| ▸ | TUBB4B known ✓ | P68371 | 4/20 | 0.99 |
| ▸ | TUBB3 known ✓ | Q13509 | 4/20 | 0.99 |
| ▸ | TUBB2A known ✓ | Q13885 | 4/20 | 0.99 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 4/20 | 0.99 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 4/20 | 0.99 |
| ▸ | TUBA1A known ✓ | Q71U36 | 4/20 | 0.99 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 4/20 | 0.99 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 4/20 | 0.99 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 4/20 | 0.99 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 4/20 | 0.99 |
| ▸ | NPC1 | O15118 | 8/20 | 0.99 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.99 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.99 |
| ▸ | MEN1 | O00255 | 2/20 | 0.99 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Docetaxel Anhydrous SCHEMBL1659765 | 1.00 | NPC1 (0.99) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL7109515 | 0.99 | TUBB4A (0.99) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL7109517 | 0.99 | TUBB4A (0.99) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL13524298 | 0.99 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL25446250 | 0.99 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL25052982 | 0.99 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL22503340 | 0.99 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL21465719 | 0.99 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL22667521 | 0.99 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL12127070 | 0.99 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107001302-A | One class water-soluble taxane analog derivative and application thereof | 江苏恩华络康药物研发有限公司 | 2017-08-01 | — | — | CN | claimed |
| CN-117580847-A | Macrolide compounds | 范德比尔特大学 | 2024-02-20 | — | — | CN | disclosed |
| CN-107056767-B | Process and intermediates for the preparation of water-soluble taxane derivatives | 江苏恩华络康药物研发有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-108653221-B | Pharmaceutical dosage forms and uses thereof | 南京三迭纪医药科技有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-108721242-B | Pharmaceutical dosage forms and uses thereof | 南京三迭纪医药科技有限公司 | 2021-03-02 | — | — | CN | disclosed |
| EP-3464597-A1 | OLIGONUCLEOTIDE PROBES AND USES THEREOF | Caris Science, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3430137-A1 | OLIGONUCLEOTIDE PROBES AND USES THEREOF | Caris Science, Inc. (US) | 2019-01-23 | — | — | EP | disclosed |
| CN-106029631-B | Carboxylic acid derivatives and application thereof in preparing prodrugs | 李勤耕 | 2018-12-28 | — | — | CN | disclosed |
| CN-107922329-A | It is used to prepare the method and intermediate of water-soluble taxane analog derivative | 江苏恩华络康药物研发有限公司 | 2018-04-17 | — | — | CN | disclosed |
| WO-2017205686-A1 | OLIGONUCLEOTIDE PROBES AND USES THEREOF | CARIS SCIENCE, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017161357-A1 | OLIGONUCLEOTIDE PROBES AND USES THEREOF | CARIS SCIENCE, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| CN-107056767-A | Method and intermediate for preparing water-soluble taxane analog derivative | 江苏恩华络康药物研发有限公司 | 2017-08-18 | — | — | CN | disclosed |
| CN-107001302-A | One class water-soluble taxane analog derivative and application thereof | 江苏恩华络康药物研发有限公司 | 2017-08-01 | — | — | CN | disclosed |
| CN-106029631-A | Carboxylic acid derivatives and application thereof in preparing prodrugs | 李勤耕 | 2016-10-12 | — | — | CN | disclosed |
| US-8541465-B2 | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid | SCIDOSE, LLC (US) | 2013-09-24 | — | — | US | disclosed |
| US-20110092580-A1 | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid | SCIDOSE LLC (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092580-A1 | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid | DLST, TTPA, LIPA | TUBB4A 1521/4885TUBB 807/4885TUBA3C 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.